Telomir Pharmaceuticals Receives Nasdaq Non-Compliance Notice for Delayed Annual Meeting
TELO sits 21% above its 52-week low of $1.12 on light trading volume (0.4× avg).
Summary
Telomir Pharmaceuticals received a notice from Nasdaq indicating non-compliance with listing rules due to its failure to hold an annual shareholder meeting, requiring the company to submit a plan to regain compliance.
Key Events · Corporate Governance and Compliance · TELO
-
Nasdaq Non-Compliance Notice Received
On January 8, 2026, Telomir Pharmaceuticals received a notice from Nasdaq for non-compliance with Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders within twelve months of their fiscal year-end.
-
No Immediate Delisting
The notice does not result in the immediate delisting of the company's securities and has no current effect on the listing or trading of its common stock on the Nasdaq Capital Market.
-
Compliance Plan Deadline
The company has until February 23, 2026, to submit a plan to regain compliance with Nasdaq Listing Rule 5620(a).
-
Path to Regain Compliance
Telomir Pharmaceuticals expects to promptly hold its annual meeting of shareholders following the completion of the SEC review process for its preliminary proxy statement, aiming to regain compliance within the applicable cure period.
Analysis · TELO · Life Sciences
Telomir Pharmaceuticals received a notice from Nasdaq for failing to hold its annual shareholder meeting within the required timeframe. While this notice does not result in immediate delisting, it signals a lapse in corporate governance and creates uncertainty regarding the company's listing status. The company must submit a compliance plan by February 23, 2026, and successfully execute it to avoid further action, which could include delisting. For a small life sciences company, maintaining a Nasdaq listing is crucial for investor confidence and access to capital, making this a critical event for shareholders to monitor.
At the time of this filing, TELO was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.8M. The 52-week trading range was $1.12 to $5.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.